Counterfeit Ozempic Identified in US Supply Chain With Fake Labels And Needles, FDA Alerts

Comments
Loading...
Zinger Key Points

On Monday, Novo Nordisk A/S NVO said it had become aware of several hundred units of Ozempic (semaglutide) injection 1 mg distributed outside the Novo Nordisk authorized supply chain in the U.S.

The seized counterfeit products feature lot number PAR0362 and illegitimate serial numbers beginning with the first eight digits 51746517.

Lot number PAR0362 is an authentic lot number. Only when the lot number is coupled with the eight digits 51746517 it is counterfeit and should not be used.

Also Read: Eli Lilly And Novo Nordisk Could Face Policy Shifts As FDA Oversight, Tariff Risks Mount

The U.S. Food and Drug Administration (FDA) says that further analyses, including extensive visual examination and chemical testing of the seized counterfeit product, are underway as the investigation continues.

Accordingly, neither Novo Nordisk nor the FDA can confirm the contents or quality of the counterfeit product, which may present a safety risk for patients who use the counterfeit product.

FDA and Novo Nordisk are testing the seized products and do not yet have information about the drugs' identity, quality, or safety.

Additionally, the analysis found the needles from the samples were counterfeit.

Accordingly, the sterility of the needles cannot be confirmed, which presents an increased risk of infection for patients who use counterfeit products.

Based on analyses completed to date, the pen label, accompanying health care professional and patient information, and carton are other confirmed counterfeit components within the seized products. 

FDA is aware of six adverse events from this lot, none of which are serious and are consistent with known common adverse reactions to authentic Ozempic, which are nausea, vomiting, diarrhea, abdominal pain, and constipation.

Price Action: NVO stock closed lower by 2.38% at $64.49 at the last check Tuesday.

Read Next:

Photo by KK Stock via Shutterstock

NVO Logo
NVONovo Nordisk AS
$64.49-2.38%

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score
Edge Rankings
Momentum
11.88
Growth
79.95
Quality
93.88
Value
6.75
Price Trend
Short
Medium
Long
Got Questions? Ask
How will counterfeit Ozempic impact Novo Nordisk sales?
Which pharmaceutical companies may benefit from increased regulation?
Could FDA scrutiny lead to growth for generic drug makers?
Will investors shift focus to pharma stocks amid safety concerns?
How might investments in drug safety technology rise from this incident?
Which healthcare stocks could face volatility due to counterfeit risks?
Are medical supply companies likely to see increased demand for legitimate products?
How will this impact stocks in the healthcare sector?
Could this lead to a surge in investments in anti-counterfeiting measures?
Which pharmaceutical sectors might be most affected by counterfeit products?
Market News and Data brought to you by Benzinga APIs

Posted In: